5Suleiman M, Aronson D, Reisner SA, et al. Admission C. reactive protein levels and 30-day mortality in patients with acute myocardi- al infarction. Am J Mcd ,2003,115:695-701.
5Uyarel H, Uzunlar B, Unal DS, et al. Effect of tirofiban therapy on ST segment resolution and clinical outcomes in patients with ST segment elevated acute myocardial infarction udergoing primary angioplasty [ J], Cardiology, 2006, 105 (3): 168-175.
6Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions: the task force for percutaneous coronary interventions of the european society of cardiology [ J]. Eur Heart J, 2005, 26 (8) : 804 - 847.
7Petronioa AS, Royal D, Musumeci G, et al. Effects of abeiximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction tread by primary coronary angioplasty [ J ]. Ear Heart J, 2003, 24 (1): 67-76.
8Yang TY, Chang ST, Chung CM, et al. Restoration of normal coronary flow with tirofiban by intracoronary administrion for no - reflow phenomenon after stent deployment [ J]. Int Heart J, 2005, 46 (1): 139 - 145.
9Ito H,Marugama A,Iwakura K,et al.Clinical implications of the no-reflow phenomenon:a predictor of complications and left ventnjcular in reperfused anterior wall myocardial infarction[J].Circulation,1996,93(5):223-228.
10Kotani J,Nanto S,Mintz GS,et al.Plaque gruel of atheromatous coronary lesion may contribute to the no-reflow phenomenon in patients with acute coronary syndrome[J].Circulation,2002,106(13):1672-1677.
